Andrew Jensen

Andrew Jensen is an associate in Goodwin’s Antitrust and Competition practice. He advises clients on antitrust and competition issues, including merger reviews, compliance, government antitrust investigations, antitrust litigation, and other regulatory issues. He has significant experience in premerger counseling, including compliance with Hart-Scott-Rodino premerger requirements, and has also successfully guided clients through investigations before the DOJ and FTC. Andrew has experience counseling clients across a wide range of industries, including healthcare, pharmaceuticals, financial services, consumer products, retail, manufacturing, among others.

In addition, Andrew has also guided healthcare clients through all phases of state “mini-HSR” transaction filings in California, Oregon, New York, and Minnesota, among others, while demonstrating thought leadership in a rapidly developing area of competition law.

Andrew is committed to pro bono service, including successfully representing clients in asylum merits hearings, in collaboration with Catholic Charities Immigration Legal Services, Community Legal Services in East Palo Alto (CLSEPA), and Lawyers for Good Government.

Andrew’s representative experience includes advising:

• Blueprint Medicines in its proposed $9.1 billion sale to Sanofi
• Zealand Pharma in its $5.3 billion partnership agreement with Roche
• Webster Equity Partners in its sale of Retina Consultants of America to Cencora, Inc. for $4.6 billion
• SpringWorks Therapeutics in its acquisition by Merck KGaA for $3.9 billion
• Webster Equity Partners in its sale of CenExel Clinical Research, Inc. to BayPine LP
• Frazier Healthcare Partners in its acquisition of BioMatrix Holdings, LLC
• Frazier Healthcare Partners in its acquisition of RevSpring
• Fuze Health in its acquisition of Alto Pharmacy for more than $1 billion
• Gubra A/S in its license agreement with AbbVie for up to $1.875 billion
• IDRx in its acquisition by GSK plc for up to $1.15 billion
• Renesas Electronics Corporation in its $345 million acquisition of Transphorm, Inc.
• Mariana Oncology in its $1 billion proposed acquisition by Novartis
• Harpoon Therapeutics in its $680 million proposed acquisition by Merck
• Orchard Therapeutics plc in its $397 million proposed acquisition by Kyowa Kirin Co., Ltd.
• iRobot in its $1.7 billion proposed acquisition by Amazon
• Inversago Pharma in its acquisition by Novo Nordisk, worth up to $1.08 billion
• PPD in its $17.4 billion acquisition by Thermo Fisher Scientific*
• Change Healthcare’s $13.8 billion acquisition by Optum*
• Hellman & Friedman in its acquisition of The NPD Group*
• BMC Stock Holdings in its $5.5 billion merger with Builders FirstSource*
• Waystar in its acquisition of eSolutions*

*Denotes experience prior to joining Goodwin.

Andrew was recognized by The Best Lawyers in America 2026 as Ones to Watch for his work in Antitrust Law.

Andrew co-created and provides regular updates to Goodwin’s resource on State Healthcare Transaction Notification (mini-HSR) Laws, and is a contributor to Goodwin’s Antitrust Trends in Technology, Life Sciences, and Healthcare series, which provides quarterly analysis and commentary on antitrust developments. His other publications include:

• Co-Author, “Oregon on the Verge of Restricting Private Equity Investment in Medical Practices,” Goodwin Client Alert, May 30, 2025
• Co-Author, “States Continue to Pursue and Expand Healthcare Market Oversight at an Unprecedented Pace, With Significant Implications for Private Equity,” Goodwin Client Alert, March 20, 2025
• Co-Author, “DOJ Sues Private Equity Firm KKR & Co. for Violations of HSR Act,” Goodwin Client Alert, January 16, 2025
• Co-Author, “Massachusetts Passes Comprehensive Revisions to Healthcare Transaction Notification Law with Significant Implications for Private Equity Healthcare Investments,” Goodwin Client Alert, January 14, 2025
• Co-Author, “United States: DOJ and FTC to Shift Focus to AI as Stringent Merger Enforcement Chills Tech Deals,” Global Competition Review’s Digital Markets Guide, October 2, 2024
• Co-Author, “Antitrust & Competition Healthcare Quarterly Update Q2 2024,” Goodwin Insight, September 18, 2024
• Co-Author, “Indiana Enacts Broad Notification Requirements for Healthcare Transactions with a Clear Focus on Private Equity,” Goodwin Client Alert, May 20, 2024
• Co-Author, “Antitrust & Competition Healthcare Year in Review 2023,” Goodwin Insight, March 11, 2024
• Co-Author, “United States: Scepticism of Tech Transactions Sparks a Step-Up in Merger Enforcement,” The Global Competition Review, March 11, 2024
• Co-Author, “FTC and DOJ Launch New Cross-Government Inquiry on the Role of Private Equity in Healthcare,” Goodwin Client Alert, March 7, 2024
• Co-Author, “US Antitrust Agencies Release Final Revised Merger Guidelines,” Goodwin Client Alert, December 19, 2023
• Co-Author, “Antitrust & Competition Healthcare Quarterly Update Q3 2023,” Goodwin Insight, November 2, 2023
• Co-Author, “US Antitrust Regulators Continue to Crack Down on Interlocking Directorates, and the FTC Expands Scope of Clayton Act to Noncorporate Entities,” Goodwin Client Alert, August 25, 2023
• Co-Author, “Antitrust & Competition Healthcare Quarterly Update Q2 2023,” Goodwin Insight, August 11, 2023